PMID- 37545101 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231028 IS - 2328-9503 (Electronic) IS - 2328-9503 (Linking) VI - 10 IP - 10 DP - 2023 Oct TI - Clinical scales in autoimmune encephalitis-A retrospective monocentric cohort study. PG - 1768-1775 LID - 10.1002/acn3.51865 [doi] AB - OBJECTIVE: Assessing severity of antibody-mediated encephalitis (AE) or paraneoplastic encephalitis (PE) requires valid and reliable scores to guide treatment decisions and predict outcome both in clinical routine and studies. We aimed to validate the prognostic value of the clinical assessment scale in autoimmune encephalitis (CASE) and the anti-NMDAR-encephalitis one-year functional status (NEOS) score in patients suffering from AE and PE in a large monocentric cohort. METHODS: We retrospectively applied the CASE and NEOS score to patients with definite AE and PE treated at a tertiary hospital. Correlations were established between the CASE and NEOS score and the modified Rankin scale (mRs). Multivariable analyses were calculated to identify predictors of outcome. RESULTS: Thirty-four patients (27 AE, 7 PE) were included. Correlations between mRS and CASE score were strongest in patients with AE compared to PE at all intervals, but in the subgroups (LGI1, NMDAR, GAD, miscellaneous surface antibodies, PE) the correlation was strongest in the interval after baseline. Patients with AE seemed to display better outcomes compared to PE, which was underlined by multivariable analysis. Improvement was mostly observed within 6-12 months after disease onset, after which little or no further improvement was noted with some exception for two patients with anti-NMDARE who recovered substantially even after 12 months of treatment. The NEOS score significantly predicted the outcome at last follow-up in patients with AE with a sensitivity of 79% at a cut-off value of 2 points (AUC 0.79, 95% CI 0.58-0.99, p = 0.04). INTERPRETATION: The CASE and NEOS score are suitable supplementary tools in addition to the mRS for capturing diverse symptoms, for grading and monitoring symptom severity. CI - (c) 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. FAU - Macher, Stefan AU - Macher S AUID- ORCID: 0000-0001-8068-1528 AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. FAU - Bsteh, Gabriel AU - Bsteh G AUID- ORCID: 0000-0002-0825-0851 AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. FAU - Hoftberger, Romana AU - Hoftberger R AUID- ORCID: 0000-0002-5769-1100 AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. AD - Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria. FAU - Berger, Thomas AU - Berger T AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. FAU - Rommer, Paulus AU - Rommer P AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. FAU - Zrzavy, Tobias AU - Zrzavy T AUID- ORCID: 0000-0001-8909-1591 AD - Department of Neurology, Medical University of Vienna, Vienna, Austria. AD - Comprehensive Center for Clinical Neurosciences & Mental health, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20230806 PL - United States TA - Ann Clin Transl Neurol JT - Annals of clinical and translational neurology JID - 101623278 RN - Hashimoto's encephalitis SB - IM MH - Humans MH - Retrospective Studies MH - Cohort Studies MH - *Hashimoto Disease/diagnosis/drug therapy MH - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/therapy PMC - PMC10578879 COIS- The authors declare no potential conflict of interest with any commercial entities relating to this study. EDAT- 2023/08/07 06:42 MHDA- 2023/10/23 00:42 PMCR- 2023/08/06 CRDT- 2023/08/07 01:02 PHST- 2023/06/19 00:00 [revised] PHST- 2023/03/07 00:00 [received] PHST- 2023/07/13 00:00 [accepted] PHST- 2023/10/23 00:42 [medline] PHST- 2023/08/07 06:42 [pubmed] PHST- 2023/08/07 01:02 [entrez] PHST- 2023/08/06 00:00 [pmc-release] AID - ACN351865 [pii] AID - 10.1002/acn3.51865 [doi] PST - ppublish SO - Ann Clin Transl Neurol. 2023 Oct;10(10):1768-1775. doi: 10.1002/acn3.51865. Epub 2023 Aug 6.